Evidence map›Paper›PMID 38327519›Full record

ArticleFrontiers in immunology2024

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.

Lorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, Eric T Tjwa, Gustav Buescher, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Jérôme Dumortier, Mar Riveiro Barciela and 15 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Lorenz KocheiseI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ignazio PisedduEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Joscha VonderlinEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Eric T TjwaEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Gustav BuescherI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Lucy MeunierEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Pia GoeggelmannDepartment of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany.
Francesca FianchiEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Jérôme DumortierEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Mar Riveiro BarcielaEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Tom J G GeversEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Benedetta Terziroli Beretta-PiccoliEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Maria-Carlota LondoñoEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Sona FrankovaEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Thomas RoesnerDepartment of Medical Oncology, National Center of Tumor Diseases (NCT) Heidelberg and Universitätsklinikum Heidelberg, Heidelberg, Germany.
Vincent JoergI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Constantin SchmidtI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Fabian GlaserI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jan P SutterI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thorben W FründtI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ansgar W LohseI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Samuel HuberI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Johann von FeldenI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Marcial Sebode *I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Kornelius Schulze *I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1326078.].

Indexed as

autoimmune disease (AID)autoimmune hepatitis (AIH)autoimmune liver diseases (AILD)immune checkpoint inhibitors (ICI)immune related adverse effects (irAEs)PD-1/PD-L1 immune checkpoint inhibitorsprimary biliary cholangitis (PBC)primary sclerosing cholangites (PSC)

Identifiers

PMID38327519
PMCPMC10848160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.